Abstract
Background: The COVID-19 pandemic has raised novel concerns for people living with MS regarding their safety.
Methods: Observational study of patients at a single comprehensive community MS center.
Results: 48 patients with MS were suspected of developing COVID-19 March to May 2020; 2 died. Of the remainder, 17 were tested for COVID-19 antibodies as part of routine care. Average age of this subgroup was 49.8y ± 11.3 (age range 32-67), 76% female. 65% were treated with an anti-CD20 drug, 12% untreated, and 6% each received glatiramer acetate, interferon, natalizumab, or teriflunomide. 59% of patients were antibody negative.
Conclusions: The low incidence of SARS CoV2 antibodies following infection suggests that certain DMTs may alter SARS CoV2-Ab response or persistence.
Keywords: Anti-B cell treatment; COVID-19; COVID-19 antibodies; Disease modifying treatment; MS; Observational study.
【저자키워드】 COVID-19, observational study, MS, Disease modifying treatment, Anti-B cell treatment, COVID-19 antibodies, 【초록키워드】 antibody, COVID-19 pandemic, Infection, interferon, observational study, persistence, female, Patient, Community, age, COVID-19 antibody, incidence, anti-CD20, Acetate, average age, routine care, Alter, Cell, tested, died, raised, treated, 【제목키워드】 SARS-CoV2, antibody, Patient,